History of graft-versus-host disease

Vriesendorp, Huibert M.; Heidt, P. J.

doi:10.1016/j.exphem.2016.05.011

Cited by 20 publications

(6 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is caused by engraftment of immunocompetent donor T lymphocytes in an immunologically compromised host showing histocompatibility differences with the donor. These differences between the host and donor result in donor T cell activation against either the recipient MHC antigens or minor histocompatibility antigens, resulting in an excess of cytokines, including TNF-α and IFN-γ [ 25 , 26 ]. GVHD is usually subdivided into acute GVHD and chronic GVHD.…”

Section: Introductionmentioning

confidence: 99%

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Zhong

Zhang

et al. 2017

J Hematol Oncol

View full text Add to dashboard Cite

BackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a challenge and is associated with poor long-term survival. Chimeric antigen receptor redirected T cells (CAR-T cells) can lead to disease remission in patients with relapsed/refractory hematological malignancies. However, the therapeutic window for infusion of CAR-T cells post allo-HSCT and its efficacy are debatable.Main bodyIn this review, we first discuss the use of CAR-T cells for relapsed cases after allo-HSCT. We then review the toxicities and the occurrence of graft-versus-host disease in relapsed patients who received CAR-T cells post allo-HSCT. Finally, we review clinical trial registrations and the therapeutic time window for infusion of CAR-T cells post allo-HSCT.ConclusionsThe treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications. However, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Zhong

Zhang

et al. 2017

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…This condition is referred as graft versus host disease and is the result of the incompatibility between the HLA system antigens of the donor and recipient. 4 Human Leukocyte Antigens (HLA), 2,5,6 which are the necessary proteins are encoded by the Major Histocompatibility Complex (MHC). 7 There are three sequential phases, which can be used to illustrate the complex cellular interactions and inflammatory cascades and which ultimately evolve to acute GVHD-These are-(i) Activation of antigen presenting cells.…”

Section: Methodsmentioning

confidence: 99%

“…Initially, the delayed deaths were said to be caused by secondary disease and it was later renamed as graft-versus-host disease (GVHD). 2 According to the National Institutes of Health (NIH), the oral features of cGVHD can be classified as-1. Diagnostic (lichen planus-like changes, hyperkeratotic plaques and reduction in mouth opening).…”

Section: Introductionmentioning

confidence: 99%

Graft Versus Host Disease- Oral Presentation

S¹,

Sithara²,

Anchan³

et al. 2017

jebmh

View full text Add to dashboard Cite

BACKGROUND Graft-versus-host disease (GVHD) is described as a potentially life-threatening complication caused by allogeneic haematopoietic cell transplantation. It is an exaggerated manifestation of a normal inflammatory mechanism in which donor lymphocytes encounter foreign antigens in an atmosphere that promote inflammation. 90% of the patients show oral features in case of cGVHD. Oral mucosal lesions and salivary gland dysfunction are the main oral features of chronic GVHD. Trismus or reduction of the mouth opening due to the perioral deposition of collagen is also commonly seen. Purpose of this review is to understand pathophysiology of oral presentations of GVHD. MATERIALS AND METHODS Review related to GVHD pathophysiology, oral lesions after haematopoietic cell transplant encompassed literature from 1966 through 2015. Review of Medline/PubMed Journals were done. RESULTS It is difficult to describe the pathophysiology of oral manifestations because there is no well accepted definition. CONCLUSION Larger well-designed clinical studies are needed to understand the pathobiology of oral cGVHD and determine best treatments for this disease.

show abstract

“…1 It was not until »10 years after that first transplant, in 1968, that the importance of genetic matching (known as human leukocyte antigen [HLA] matching) was realized. 2 By 1973, bone marrow transplants were performed from nonÀtwinrelated and nonrelated donors. Today, bone marrow transplants are commonly used for when a patient needs to replace the blood-forming stem cells that have been damaged from disease, high doses of radiation, or anticancer drugs.…”

Section: T a G G E D H 1 History Of The Use Of Stem Cell Therapyt A Gmentioning

confidence: 99%

Induced Pluripotent Stem Cells: The Most Versatile Source for Stem Cell Therapy

Glicksman

2018

Clinical Therapeutics

View full text Add to dashboard Cite

Cell therapy has existed since the first bone marrow transplant in the 1950s involving identical twins. The blood-forming stem cells were used to restore healthy blood cells for the twin with leukemia. It was not until 1968 that genetic matching (known as human leukocyte antigen matching) was known to be important, and not until 1973 that bone marrow transplants were performed from non-twin-related and nonrelated donors. The most important application of human stem cells is for the generation of cells and tissues for cell-based therapies. Currently, donated organs and tissues are often the only option to replace diseased, injured, or destroyed tissue. The availability for these transplantable tissues and organs is very limited, however. To satisfy the demand for a source for these cells and tissues, induced pluripotent stem cells that have been differentiated into specific cell types can serve as a renewable source of replacement cells and tissues. A bank of suitable human leukocyte antigen-matched cells will be an important source providing immediate availability of cells that are readily scalable, economical, and well characterized. Areas of active pursuit with stem cell therapy is being investigated for treating diseases such as macular degeneration, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, rheumatoid arthritis, and neurodegenerative diseases. This article describes the advantages and hurdles for the use of induced pluripotent cells as the starting material for a source of replacement cells for regenerative medicine.

show abstract

History of graft-versus-host disease

Cited by 20 publications

References 59 publications

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Graft Versus Host Disease- Oral Presentation

Induced Pluripotent Stem Cells: The Most Versatile Source for Stem Cell Therapy

Contact Info

Product

Resources

About